PROCEPT BioRobotics : Investor Presentation – May 2024

VISION: BECOME THE BPH TREATMENT OF CHOICE

FOR ALL PROSTATES

May 2024

© 2024 PROCEPT BioRobotics Corporation. All Rights Reserved.

Safe Harbor Statement

This presentation and accompanying oral presentation contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the expected financial results of PROCEPT BioRobotics Corporation (the "Company"). Words such as "anticipates," "believes," "expects," "intends," "projects," "anticipates," and "future" or similar expressions are intended to identify forward-

looking statements. Any forward-looking statements made by us in this presentation speaks only as of the date on which it was made and are based on management's current expectations of future events, assumptions, estimates, and beliefs, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward- looking statements. Factors that could cause actual results to differ materially from those described in the forward-looking statements include, among others: (i) the rate and degree of market acceptance of the AQUABEAM Robotic System and Aquablation therapy and descriptions of the Company's revenues, gross margin, profitability, operating expenses, or installed base growth, (ii) the establishment and maintenance of consistent and favorable payment policies for Aquablation therapy, (iii) the rate of growth of the commercial sales and marketing organization and the ability to manage this anticipated growth,

1. the impact on volumes of elective procedures performed by health care providers and hospital medical device budgets, (v)the effects of increased competition as well as innovations by new and existing
   competitors in the market for treatments for benign prostatic hyperplasia, (vi) the ability to obtain the required regulatory approvals and clearances to market and sell the AQUABEAM Robotic System in certain

other countries, (vii) the development and protection of future innovation, (viii) dependence on alimited number of third-party suppliers for components of the AQUABEAM Robotic System, (ix) the maintenance of intellectual property rights and the ability to operate the business without infringing the intellectual property rights and proprietary technology of third parties, (x) the successful completion of clinical trials and (xi) the adoption of our technology for additional indications.

This presentation and the accompanying oral presentation also contain estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to suchestimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we compete are necessarily subject to a high degree of uncertainty and risk.

Factors that could cause actual results to differ materially from those contemplated in this presentation can be found in theRisk Factors section of the Company's public filings with the Securities and Exchange Commission ("SEC"), including the Annual Report on Form 10-K filed with the SEC on February 28, 2024 and any current and periodic reports filed thereafter, available at www.sec.gov.

Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact are forward-looking statements. Except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this presentation due to the risks and uncertainties inherent inthe Company's business. In light of the foregoing, investors are urged not to rely on any forward-looking statement or third-party data in reaching any conclusion or making any investment decision about any securities of the Company.

This presentation regarding the Company shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Sales and offers to sell PROCEPT BioRobotics securities will only be made in accordance with the Securities Act of 1933, as amended, and applicable SEC regulations, including prospectus requirements.

2	© 2024 PROCEPT BioRobotics Corporation. All Rights Reserved.

Use of Non-GAAP Financial Information

In addition to financial information presented in accordance with U.S. generally accepted accounting principles ("GAAP"), this presentation and the accompanying oral statements include certain non-GAAP financial measures, which include non-GAAP Adjusted EBITDA. The Company defines Adjusted EBITDA as earnings before interest expense, taxes, depreciation and amortization and stock-based compensation. The Company believes that presenting Adjusted EBITDA provides useful supplemental information to investors about the Company in understanding and evaluating its operating results, enhancing the overall understanding of its past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by its management in financial and operational decision making. However, there are a number of limitations related to the use of non-GAAP measures and their nearest GAAP equivalents. For example, such measures may exclude significant expenses required by GAAP tobe recognized in our financial statements. Other companies may calculate non-GAAP measures differently, or may use other measures to calculate their financial performance, and therefore any non-GAAP measures the Company uses may not be directly comparable to similarly titled measures of other companies. Non-GAAP financial measures are not a substitute for or superior to measures of financial performance prepared in accordance with GAAP and should not be considered as an alternative to any other performance measures derived inaccordance with GAAP. Any non-GAAP measure is presented for supplemental informational purposes only and should not be considered a substitute for or superior to financialinformation presented in accordance with GAAP. A reconciliation of these measures to the most directly comparable GAAP measures is included at the end of this presentation.

3	© 2024 PROCEPT BioRobotics Corporation. All Rights Reserved.

Aquablation Therapy:

Uniquely Positioned to Become the BPH Standard of Choice for All Prostate Sizes and Shapes

A BPH therapy that addresses the compromise between safety and efficacy of alternative surgical interventions1,2

F i r s t - o f - i t s - K i nd Technol og y	$20B+
Only automated waterjet for BPH
Robust IP portfolio with high barriers to entry
C om p el l i ng C l i ni ca l Evi d ence	U.S. BPH
Surgical Market
Strong and growing base of clinical evidence -over 150 peer-
Opportunity
reviewed publications
Only BPH technology randomized against TURP, the historical
standard of care for surgical intervention3
~95% Pa ti ents A cces s to A q ua b l a ti on Ther a p y
Strong KOL support
Inclusion in clinical guidelines
Pr oven C om m er ci a l Str a teg y
Well-defined customer base and efficient sales infrastructure
Capital equipment with recurring disposable and service revenues

4	© 2024 PROCEPT BioRobotics Corporation. All Rights Reserved.

Benign Prostatic Hyperplasia (BPH)

A Significant Men's Health Disease in the U.S.

NORMAL PROSTATE		#1
		Reason men visit the urologist

1 in 2

Estimated men ages 51-60 have BPH and prevalence increases over time

ENLARGED PROSTATE (BPH)			99%
		Men with BPH say symptoms impact Quality of Life1

~40M

Men in the U.S. that currently have BPH2

2x

5

Men >65 years old in the U.S. expected to double by the year 20602

© 2024 PROCEPT BioRobotics Corporation. All Rights Reserved.

Large Market & Significant Unmet Need

U.S. men actively

3.8M

MANAGED for BPH

12M	6.7M
1.1M
	400K

WATCHFUL WAITERS

Choose to do nothing and suffer BPH symptoms

PHARMACEUTICALS

Suffer dosing adjustments and side effects

PHARMA FALLOUT

Delay surgery despite medication failure

SURGERIES ANNUAL

Compromise between

safety & efficacy outcomes

$16B

$3B

$1B

8.2M

Actively

TREATED

for BPH

$20B+

U.S. BPH

Surgical Market

Opportunity

6	© 2024 PROCEPT BioRobotics Corporation. All Rights Reserved.

Limitations: Pharmaceutical Therapy

FIRST-LINE TREATMENTS

MINIMAL IMPACT ON SYMPTOMS & HIGH SIDE EFFECT PROFILE

•

•

Alpha-blockers: relax the prostate

5-ARIs: shrink the prostate

• Minimal impact on symptom relief (IPSS reduction: ~5 points) and flow improvement (~2.5 mL/s improvement)
• Side effects may include ejaculatory dysfunction, erectile dysfunction, headaches, dizziness, and loss of libido
• Long-termuse increases risk of cardiac failure and dementia

Up to 30%	of patients stop BPH
meds within 2 years

7	© 2024 PROCEPT BioRobotics Corporation. All Rights Reserved.

Unmet Need in Surgical Intervention

UNMET NEED:

P R I O R I T I Z E	SAFETY & EFFICACY IN ALL PROSTATES
	ALL SIZES, ALL SHAPES
S E X U A L
F U N C T I O N	&
C O N T I N E N C E
P R E S E R V A T I O N
S Y M P T O M
R E L I E F
		small	medium	large	extra large
		(30-40mL)	(40-80mL)	(80-150mL)	(150mL+)

P R I O R I T I Z E
S Y M P T O M
R E L I E F
S E X U A L
F U N C T I O N	&
C O N T I N E N C E
P R E S E R V A T I O N

N o n - Re s e c t i ve

TURP & PVPEnucleation & Simple

MIST

PVP = Photovaporization of Prostate

MIST: Minimally Invasive Surgical Technology

Re s e c t i ve

8

© 2024 PROCEPT BioRobotics Corporation. All Rights Reserved.

Resective Surgery: Overview & Limitations

290K Procedures in 20191

PROSTATE TISSUE ISREMOVED

DURING PROCEDURE

• TURP
• Laser
• • PVP (Photo-vaporization of Prostate)
  • Enucleation (HoLEP, ThuLEP, GreenLEP)
• Simple (Open, Laparoscopic, Robotic)

FAVORABLE EFFICACY BUT

WEAK SAFETY PROFILE WITH MANY SIZE & SHAPE LIMITATIONS

Efficacy

• Sustained, high impact on symptom relief (IPSS reduction: ~15 points)

Safety

• High rates of irreversible complications: incontinence, ejaculatory dysfunction, erectile dysfunction

Procedure

•

•

•

Intraoperative visualization limited to cystoscopy

Size and shape limitations for TURP and PVP

Manual techniques dependent on surgeon skill; variability in

resection times

9

© 2024 PROCEPT BioRobotics Corporation. All Rights Reserved.

Resective Surgery: Summary of Key Safety Data

TURP1,2	PVP1,2	Enucleation1,2,3	Simple
Prostatectomy1,4

General Prostate Size	< 80mL	< 80mL	> 80mL	> 100mL
	Treated
		As high as	As high as	As high as	As high as
Complications	Incontinence
2%	2%	33%	8%
Erectile dysfunction	As high as	As high as	As high as	As high as
14%	20%	8%	2-3%
Irreversible
Ejaculatory	As high as	As high as	As high as	As high as
dysfunction	89%	50%	77%	90%

10

© 2024 PROCEPT BioRobotics Corporation. All Rights Reserved.